Elevation Oncology Inc

NASDAQ:ELEVUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.

Contact Information

Headquarters

101 Federal Street, Suite 1900BOSTON, MA, United States 02110

Phone

716-371-1125

Fax

302-697-4597

Executives

Chairman of the Board

Steven Elms

President, Chief Executive Officer, Director

Joseph Ferra

Chief Financial Officer

Tammy Furlong

Chief Scientific Officer

David Dornan

Chief Medical Officer

Valerie Jansen